TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
| Metabolism | Amino acids undergo hepatic metabolism via transamination and deamination; dextrose is metabolized via glycolysis and oxidative phosphorylation. Insulin promotes cellular uptake. |
| Excretion | Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally. |
| Half-life | Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia). |
| Protein binding | Not significant for amino acids or dextrose; amino acids are unbound (<10%), dextrose does not bind to proteins. |
| Volume of Distribution | Amino acids distribute similar to extracellular fluid (~0.2-0.3 L/kg); dextrose distributes in total body water (~0.6 L/kg). |
| Bioavailability | Intravenous: 100% (directly enters systemic circulation). |
| Onset of Action | Intravenous: Nutritional effects begin within minutes as amino acids and dextrose enter systemic circulation; metabolic effects (protein synthesis, glucose utilization) occur within hours. |
| Duration of Action | Intravenous: Nutrient provision lasts as long as infusion continues; metabolic effects persist for hours after cessation, depending on individual metabolic state. |
| Molecular Weight | Amino acids: 75-204 Da; Dextrose: 180.16 Da |
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: Use with caution; monitor serum electrolytes and osmolarity. Reduce dose or use renal-specific amino acid formulation if severe impairment (GFR <25 mL/min). |
| Liver impairment | Child-Pugh B or C: Contraindicated; avoid in hepatic encephalopathy. In mild impairment (Child-Pugh A), use with caution and monitor ammonia. |
| Pediatric use | Weight-based: 1.5-3 g/kg/day of amino acids (equivalent to 54-109 mL/kg/day of this solution) with dextrose 3-6 mg/kg/min. Titrate based on metabolic tolerance. |
| Geriatric use | Elderly: Initiate at lower doses (e.g., 50-75% of standard) due to decreased renal function; monitor fluid and electrolyte balance closely; use with caution in heart failure. |
| 1st trimester | Amino acids and dextrose are essential nutrients; no known teratogenic risk. Use only if clearly needed. |
| 2nd trimester | Considered safe for maternal and fetal nutrition; monitor for metabolic complications. |
| 3rd trimester | Safe for maternal and fetal nutrition; avoid overhydration and electrolyte imbalances. |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).
| Placental transfer | Amino acids and glucose cross the placenta via active transport and facilitated diffusion. |
| Breastfeeding | Components are normal constituents of breast milk; no expected adverse effects. Compatible with breastfeeding. |
| Lactation Rating | Safe |
| Teratogenic Risk | Parenteral amino acid and dextrose solutions are essential nutrients; no teratogenic risk documented in first trimester. Use in second and third trimesters is common for maternal nutritional support without known fetal harm. However, hyperglycemia or electrolyte imbalances from improper administration may indirectly affect fetal development. |
| Fetal Monitoring | Monitor serum electrolytes, blood glucose (prevent hyperglycemia/hypoglycemia), fluid balance, renal function (BUN, creatinine), liver function, and acid-base status. Fetal monitoring indicated if maternal stabilization is required. |
| Fertility Effects | No known adverse effects on fertility. Nutritional support may improve fertility in malnourished patients. |
■ FDA Black Box Warning
Not for use in patients with severe metabolic acidosis, hypersensitivity to any component, or inborn errors of amino acid metabolism. Risk of pulmonary edema due to fluid overload, especially in renal/cardiac impairment. Hyperglycemia or hypoglycemia may occur with dextrose infusion.
| Serious Effects |
Severe electrolyte disordersSevere metabolic acidosisHyperglycemia not controlled with insulinKnown hypersensitivity to any componentInborn errors of amino acid metabolism (e.g., maple syrup urine disease)
| Precautions | Monitor fluid and electrolyte balance, blood glucose, and liver function regularly, Use with caution in renal/hepatic impairment, heart failure, diabetes mellitus, Risk of refeeding syndrome in severely malnourished patients, Do not administer if solution is discolored or contains particulate matter |
| Food/Dietary | Do not mix with food or administer orally. No specific food interactions but monitor glucose if patient is also eating. Avoid concurrent use of oral tube feedings without adjustment. |
| Clinical Pearls | TRAVASOL 2.75% IN DEXTROSE 15% is a hypertonic parenteral nutrition solution administered via central venous catheter only. Monitor serum electrolytes, glucose, renal function, and liver enzymes closely. Abrupt discontinuation may cause hypoglycemia; taper if possible. Do not administer peripheral due to high osmolarity (~1170 mOsm/L). Check for line patency and catheter placement before infusion. |
| Patient Advice | This solution is given through a large vein in your chest (central line) because it is concentrated. · Report any signs of infection at the catheter site (redness, swelling, pain) or fever. · You may need frequent blood tests to check your blood sugar, electrolytes, and organ function. · Do not stop the infusion suddenly without medical supervision to avoid low blood sugar. · Tell your healthcare provider if you have diabetes, kidney problems, or fluid buildup. |
Loading safety data…